Zeal Asset Management LTD Hutchmed (China) LTD Transaction History

Zeal Asset Management LTD

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 03, 2022	SELL	$8.59 - $20.77 $2.94 Million - $7.1 Million	-341,789 Reduced 44.8%	421,140 $5.08 Million
Q1 2022 May 06, 2022	SELL	$15.52 - $35.65 $20 Million - $45.9 Million	-1,286,965 Reduced 62.78%	762,929 $14.7 Million
Q4 2021 Feb 11, 2022	SELL	$28.89 - $35.33 $15.2 Million - $18.6 Million	-527,745 Reduced 20.47%	2,049,894 $73.2 Million
Q3 2021 Nov 04, 2021	BUY	$35.66 - $42.94 $8.48 Million - $10.2 Million	237,754 Added 10.16%	2,577,639 $94.8 Million
Q2 2021 Aug 06, 2021	BUY	$23.7 - $39.27 $7.31 Million - $12.1 Million	308,530 Added 15.19%	2,339,885 $93.4 Million
Q1 2021 May 10, 2021	SELL	$27.01 - $36.8 $17.6 Million - $24 Million	-652,763 Reduced 24.32%	2,031,355 $57.4 Million
Q4 2020 Feb 11, 2021	SELL	$27.51 - $34.36 $233,642 - $291,819	-8,493 Reduced 0.32%	2,684,118 $84.5 Million
Q3 2020 Nov 03, 2020	BUY	$25.8 - $34.61 $31.1 Million - $41.7 Million	1,204,641 Added 80.96%	2,692,611 $86.5 Million
Q2 2020 Aug 04, 2020	BUY	$17.65 - $28.05 $25.6 Million - $40.7 Million	1,450,909 Added 3914.92%	1,487,970 $40.7 Million
Q1 2020 May 12, 2020	BUY	$15.19 - $29.51 $562,956 - $1.09 Million	37,061 New	37,061 $681,000

6.88M

6.2K

1.1K

Ticker HCM
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 172,955,008
Market Cap $2.47B
Description
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...

Get notified when there are updates to the investment portfolio of Zeal Asset Management LTD, based on Form 13F filings with the SEC.

Stay updated on Zeal Asset Management LTD with notifications on news.